...
机译:孕激素代谢型基因型联合激素替代疗法在绝经后乳腺癌风险中的药理遗传调控
Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics and Epidemiology University of Pennsylvania Philadelphia PA;
Abramson Cancer Center University of Pennsylvania Philadelphia PA;
Division of Oncology Children's Hospital of Philadelphia Philadelphia PA;
Department of Medicine University of Pennsylvania Philadelphia PA;
Johnson and Johnson Pharmaceutical Research and Development Titusville NJ;
机译:稀土:“绝经后乳腺癌风险中孕激素代谢基因型联合激素替代治疗的药代动力学调节”
机译:孕激素代谢基因型联合激素替代疗法在绝经后乳腺癌中的药理遗传调节风险。
机译:绝经后乳腺癌风险中缺乏雌激素代谢基因型和联合激素替代疗法之间的作用修饰。
机译:绝经后孕激素的剂量孕激素治疗和子宫内膜癌的风险
机译:绝经后妇女的体育锻炼,激素替代疗法和胰岛素抵抗性冠状动脉疾病危险因素
机译:绝经后妇女当前激素替代治疗的乳腺癌风险
机译:绝经后乳腺癌风险黄体酮 - 代谢基因型组合激素替代治疗的药物发生调节